10-K · March 13, 2026
Ernexa is a preclinical synthetic allogeneic iMSC company focused on ERNA-101 (IL‑7/IL‑15) for platinum‑resistant ovarian cancer and ERNA‑201 (IL‑10) for autoimmune disease. The 2025 10‑K highlights regulatory progress…
Earnings analysis · 10-Q
ERNA earnings analysis
Filed May 11, 2026 · Our reading of the company's report
The latest report
Ernexa Therapeutics reported a net loss of $5.5 million in Q1 2026, an improvement from a $8.2 million loss in Q1 2025, driven by an increase in operating expenses, including a significant goodwill impairment charge.…
Read full summary
Ernexa Therapeutics reported a net loss of $5.5 million in Q1 2026, an improvement from a $8.2 million loss in Q1 2025, driven by an increase in operating expenses, including a significant goodwill impairment charge. Revenue remains absent as the company continues its pre-clinical development phase for its lead product candidate ERNA-101.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Reduction in Net Loss
Net loss narrowed to $5.506 million in Q1 2026, compared to $8.202 million in Q1 2025, marking a $2.696 million improvement.
-
Increased Operating Expenses
Total operating expenses rose to $5.590 million in Q1 2026, up from $2.730 million in Q1 2025 due to heightened R&D costs and a goodwill impairment.
-
Cash Position Improvement
Cash increased by $7.293 million in Q1 2026, bolstered by $9.5 million from a public offering.
-
No Revenue Reported
The company reported no revenues for both Q1 2026 and Q1 2025, maintaining a zero revenue status.
-
Goodwill Impairment
Recognized a $2.0 million impairment of goodwill in Q1 2026 with no remaining goodwill balance as of March 31, 2026.
-
Strong Cash Balance
Cash on hand was approximately $9.2 million as of March 31, 2026, after accounting for cash used in operations.
What to watch
-
Continued Operating Losses
Cumulatively, the company has an accumulated deficit of approximately $251.1 million as of March 31, 2026.
-
Liquidity Risks
Projected cash needs exceed current resources; as of April 30, 2026, cash was approximately $8.3 million, below operational requirements.
-
Regulatory Approval Uncertainty
The company remains in pre-clinical stages with no product sales or revenue, delaying potential future cash inflows.
Management's outlook
Company remains in pre-clinical stages and did not provide explicit forward guidance.
Earlier filings 4
10-Q · November 7, 2025
Ernexa reported zero revenue for the three months ended September 30, 2025 and a net loss of $1,240 (loss per share $0.15). Cash rose to $3,047 (in thousands) following a $7.2 million equity raise in the nine months,…
10-Q · May 7, 2025
Ernexa reported no revenue and a net loss of $(8,202) (three months ended March 31, 2025), or $(0.15) per share, driven by a $5,335 charge for a forward sales contract and lower operating expenses versus the prior year.…
10-K · March 12, 2025
Eterna Therapeutics is a preclinical allogeneic iMSC cell therapy company that completed a material September/October 2024 recapitalization, in‑licensed a broad patent portfolio and entered an Exclusive License &…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.